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Purpose: The aim of this study was to determine differences in the expression profiles of transforming growth factor
(TGF) β isoforms in the fragments of anterior lens capsules (ALCs) and peripheral blood mononuclear cells (PBMCs) of
pediatric patients with congenital and traumatic cataracts.
Methods: Forty children with congenital cataracts (19 girls and 21 boys) and 22 children with traumatic cataracts (six
girls and 16 boys) participated in the study. Fragments of ALCs obtained during cataract surgery and whole blood samples
were analyzed. Quantification of TGFβ1, TGFβ2, and TGFβ3 mRNA was performed by real-time quantitative reverse
transcription (QRT)-PCR using SYBR Green I chemistry.
Results: TGFβ1, TGFβ2, and TGFβ3 mRNA was detected in all the studied samples. Significant differences were found
for TGFβ1 and TGFβ2 expression profiles in PBMCs between the patients with congenital and traumatic cataracts. The
expression profiles of TGFβ isoforms in ALCs did not differ significantly between the groups.
Conclusions: Overexpression of TGFβ1 and TGFβ2 in the PBMCs of patients with congenital cataracts might indicate
that these cytokines are involved in the development of lens opacity.
Cataracts represent a degenerative disorder of the lens,
and  remain  a  leading  cause  of  blindness  worldwide  [1].
However,  the  molecular  mechanisms  of  the  formation  of
congenital and traumatic cataracts are still poorly understood.
The identification of molecular and genetic events involved
in these diseases may be essential for the better understanding
of cataracts, as well as for the development of diagnostic
markers and novel treatment strategies.
Transforming growth factor (TGF) β is a strong candidate
inducer  of  the  epithelial–mesenchymal  transition  and
extracellular  matrix  production,  which  characterize
congenital and traumatic cataracts in the human lens [2,3]. In
addition, the evidence from animal studies in vitro and in vivo
supports  the  hypothesis  of  the  cataractogenic  potential  of
TGFβ [2,4-6].
Five members of the TGFβ family have been identified.
However,  only  TGFβ1,  TGFβ2,  and  TGFβ3  have  been
demonstrated to be expressed in mammals [7]. Each isoform
is encoded by unique genes of different chromosomal location
[8], and reveals a 64–85% amino acid sequence homology
[9]. All TGFβ isoforms have a similar biologic effect in vitro,
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but  in  vivo  they  are  generally  characterized  by  varied
expression  levels  and  different  functions.  Their  biologic
activity  depends  on  quantitative  relationships  between
individual isoforms [10,11].
Members  of  the  TGFβ  family  regulate  fundamental
aspects  of  cellular  functions,  including  cell  growth,
differentiation,  inflammation,  and  wound  healing  [9-15].
Additionally, substantial evidence also implicates the role of
TGFβ in many human diseases [2,4,11], including fibrotic
diseases  of  the  eye  [5,6,16-18].  The  relationship  between
TGFβ levels and a degree of fibrosis in various organs is well
documented [19,20].
Most researchers determine only the TGFβ protein level
using  immunoenzymatic  methods  [20-26].  It  should  be
mentioned that the change in the protein level is preceded by
the alteration of gene transcriptional activity encoding this
protein. Many attempts have been made to identify proteins
in serum or mRNA in peripheral blood mononuclear cells
(PBMCs), which could be easily accessed and act as markers
of intratissue processes in various diseases [19,27]. However,
there are no published data regarding differences between
mRNA levels of all three TGFβ isoforms in the anterior lens
capsules  (ALCs)  and  PBMCs  of  pediatric  patients  with
congenital and traumatic cataracts.
In  the  present  study,  real-time  quantitative  reverse
transcription  (QRT)-PCR  was  applied  to  investigate  the
changes in TGFβ1, TGFβ2, and TGFβ3 gene expression in
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3025fragments of ALCs and PBMCs from pediatric patients with
congenital and traumatic cataracts. Quantitative relationships
between mRNA levels of these three TGFβ isoforms were
analyzed.
METHODS
The patient group comprised 40 individuals (19 girls and 21
boys,  mean  age  9.8  years;  range  4.7–17.3  years)  with
clinically  diagnosed  congenital  cataracts.  The  comparison
group consisted of 22 individuals (six girls and 16 boys, mean
age  11.4;  range  3.9–17.9  years)  with  clinically  diagnosed
traumatic cataracts (Table 1), treated in the Department of
Ophthalmology,  University  Hospital  No.  5,  Medical
University of Silesia, Katowice, Poland. The diagnosis of
traumatic cataracts was based on the Birmingham Eye Trauma
Terminology System [16]. The mean time interval between
injury and cataract surgery was 14.9 months (range 0.2–156.2
months).
The criteria for inclusion in the molecular analysis were
as follows: age ≤18 years, no inflammatory conditions (before
the  surgery,  all  children  were  examined  by  an
anesthesiologist, pediatrician, ear, nose, and throat specialist,
and dentist), and no systemic disease. In the case of children
with congenital cataracts, we also excluded local disorders
such  as  persistent  hyaloid  vessels,  small  cornea,  and
microphthalmia.
The study was approved by the Bioethics Committee of
the Medical University in Katowice (KNW/0022/KB1/63/I/
09) in accordance with the Declaration of Helsinki regarding
medical research involving human subjects. The study and its
purpose were explained to each participant or his or her legal
guardian, who gave informed written consent.
Tissues: Circular sections of ALCs with attached anterior
lens epithelial cells were obtained during cataract surgery, and
were stored for 48 h at −70 °C until RNA extraction. Venous
blood samples were collected into EDTA-containing tubes,
and a 7.5 ml sample from each patient was centrifuged on a
Ficoll-Conray  gradient  (specific  gravity  1.077;
Immunobiological  Co.,  Gumma,  Japan)  immediately  after
blood collection.
Ribonucleic acid extraction from tissue specimens: Total
RNA  was  extracted  from  PBMCs  and  from  ALCs  using
TRIzol  reagent  (Invitrogen,  Carlsbad,  CA).  RNA  extracts
were  treated  with  DNase  I  (MBI  Fermentas,  Vilnius,
Lithuania) according to the manufacturer’s instructions. The
quality  of  extracts  was  checked  electrophoretically  using
0.8% agarose gel stained with ethidium bromide. The results
were  analyzed  and  recorded  using  the  1D  Bas-Sys  gel
documentation  system  (Biotech-Fisher,  Perth,  Australia).
Total  RNA  concentration  was  determined  by
spectrophotometric measurement in 5 μl capillary tubes using
the Gene Quant II RNA/DNA Calculator (Pharmacia Biotech,
Cambridge, UK).
Real-time quantitative reverse transcription polymerase
chain reaction assay: Gene expression of TGFβ1, TGFβ2,
TGFβ3,  and  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) genes were evaluated using real-time QRT–PCR
and SYBR Green I chemistry (SYBR Green Quantitect RT–
PCR  Kit;  QIAGEN,  Valencia,  CA).  The  analysis  was
performed  using  an  Opticon™  DNA  Engine  Continuous
Fluorescence Detector (MJ Research, Watertown, MA). All
samples were tested in triplicate. GAPDH was included to
monitor the QRT–PCR efficiency. Oligonucleotide primers
specific  for  TGFβ1,  TGFβ2,  TGFβ3,  and  GAPDH  were
described previously by Strzalka et al. [9,15] and Ercolani et
al. [28] (Table 2). The thermal profile for one-step RT–PCR
was as follows: reverse transcription at 50 °C for 30 min,
denaturation at 95 °C for 15 min, and 50 cycles consisting of
TABLE 1. SELECTED CLINICAL FEATURES OF THE PATIENTS WITH CLINICALLY DIAGNOSED CONGENITAL OR TRAUMATIC CATARACTS.
Characteristic Congenital cataract (n=40) Traumatic cataract (n=22)
Gender
F 19 6
M 21 16
Age (years) 9.8 (4.7–17.6) 11.3 (3.9–17.9)
Eye
Right 18 9
Left 22 13
Mean time interval between injury and cataract
surgery (months)
- 14.9 (0.2–156.2)
Mean age at the time of injury (years) - 10.2 (3.7–17.6)
Type of trauma (BETTS*)
Penetrating - 22
        Values of clinical parameters are expressed as means (minimum-maximum). Abbreviations M and F stand for male and female
        participants, respectively. *BETTS - Birmingham Eye Trauma Terminology System.
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3026temperatures: 94 °C for 15 s, 60 °C for 30 s, and 72 °C for 30
s. The point at which a PCR product is first detected above a
fixed threshold, termed a cycle threshold (Ct), was determined
for each sample, and an average Ct of triplicate samples was
calculated.  Each  run  was  completed  using  melting  curve
analysis to confirm the specificity of amplification and the
absence of primer dimers. RT–PCR products were separated
on 6% polyacrylamide gels and visualized with silver salts.
Quantification of expression of target genes: To quantify
the  results  obtained  by  RT–PCR  for  TGFβ1,  TGFβ2,
TGFβ3, and GAPDH, a standard curve method was employed
[9,15]. Commercially available standards of β-actin (ACTB)
cDNA (TaqMan® DNA Template Reagent Kit; PE Applied
Biosystems,  Inc.,  Foster,  CA)  were  used  at  five  different
concentrations  (0.6,  1.2,  3.0,  6.0,  and  12.0  ng/µl)  to
simultaneously  detect  the  expression  profile  of  each
investigated  gene.  For  standards,  the  calculation  of  copy
number values was based on the following relationship: 1 ng
of DNA=333 genome equivalents (PE Applied Biosystems).
Amplification  plots  for  each  dilution  of  a  commercially
available standard template were used to determine Ct values
[9,15]. A standard curve was generated by plotting Ct values
against the log of the known amount of ACTB cDNA copy
numbers. Correlation coefficients for standard curves ranged
from 0.988 to 0.995, indicating a high degree of confidence
for measurement of the copy number of molecules in each
sample.  The  copy  numbers  of  analyzed  mRNAs  were
calculated from linear regression of the standard curve.
Statistical analyses: Statistical analyses were performed
using Statistica 8.0 software (StatSoft, Tulsa, OK), and the
level of significance was set at p<0.05. Values were expressed
as  median  (Me)  with  the  25th  and  75th  quartiles.
Nonparametric tests were used for statistical analyses because
the Shapiro-Wilk test indicated that the data were not normally
distributed. The Kruskal–Wallis test and post hoc multiple test
based on average ranks were applied to assess differences in
the expression of TGFβ isoforms. Intergroup comparison of
the gene expression under investigation was performed with
the Mann–Whitney U test. Correlations were evaluated using
the Spearman rank correlation test.
RESULTS
Specificity of the real-time reverse transcription polymerase
chain reaction assay: RT–PCR specificity for the target genes
was confirmed experimentally on the basis of amplimers’
melting temperatures. For each RT–PCR product, a single
peak at expected temperatures was observed: TGFβ1, 85.4 °C;
TGFβ2, 80.0 °C; TGFβ3, 80.6 °C; and GAPDH, 80.1 °C (data
not shown). Gel electrophoresis also revealed the presence of
a single product of predicted length (data not shown).
Differences in transforming growth factor β1, β2, and β3
messenger ribonucleic acid between anterior lens capsules
and peripheral blood mononuclear cells: In this part of the
study, the expression of TGFβ1, TGFβ2, and TGFβ3 was
analyzed  by  real-time  QRT–PCR.  Then,  the  quantitative
relations  between  the  mRNA  of  these  three  isoforms  in
congenital and traumatic cataracts were evaluated.
TGFβ1, TGFβ2, and TGFβ3 isoforms were detected in
ALC  and  PBMC  samples  obtained  from  patients  with
congenital and traumatic cataracts (Figure 1A,B).
A comparative analysis of all TGFβ mRNA copies/µg of
total RNA revealed that TGFβ1 was a predominant isoform
in the ALCs of patients with congenital cataracts. There was
no  statistically  significant  difference  between  TGFβ1
(Me=9162) and TGFβ2 (Me=5427) mRNA levels (p=0.113,
post  hoc  test).  However,  the  mRNA  level  of  TGFβ3
(Me=2470)  was  significantly  lower  than  those  of  TGFβ1
(p<0.001, post hoc test) and TGFβ2 (p<0.001, post hoc test).
In  the  PBMCs  of  patients  with  congenital  cataracts,  the
expression  of  TGFβ3  (Me=9395)  was  the  highest  and
significantly  greater  than  those  of  TGFβ1  (Me=4475,
p=0.015, post hoc test) and TGFβ2 (Me=343, p<0.001). The
mRNA level of TGFβ1 was also significantly greater than that
of TGFβ2 (p<0.001, post hoc test).
The quantitative relations between mRNA of these three
isoforms were similar in the patients with clinically diagnosed
traumatic  cataracts.  TGFβ1  was  also  the  main  isoform  in
TABLE 2. CHARACTERISTIC OF PRIMERS USED FOR REAL-TIME QRT-PCR.
Gene Sequence of primers Length of amplicon (bp) Tm (ºC)
GAPDH Forward: 5’-GAAGGTGAAGGTCGGAGTC-3’ 226 80
  Reverse: 5’-GAAGATGGTGATGGGATTC-3’    
TGFβ1 Forward:5’-TGAACCGGCCTTTCCTGCTTCTCATG-3’ 151 85
  Reverse: 5’-GCGGAAGTCAATGTACAGCTGCCGC-3’    
TGFβ2 Forward: 5’-TACTACGCCAAGGAGGTTTACAAA-3’ 201 80
  Reverse: 5’-TTGTTCAGGCACTCTGGCTTT-3’    
TGFβ3 Forward: 5’-CTGGATTGTGGTTCCATGCA-3’ 121 81
  Reverse: 5’-TCCCCGAATGCCTCACAT-3’    
           bp – base pairs; Tm -melting temperature.
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3027ALCs.  The  mRNA  levels  of  TGFβ1  (Me=10501)  and
TGFβ2 (Me=7380) were not statistically significant (p=0.226,
post hoc test). However, the expression of TGFβ3 (Me=1573)
was found to be significantly lower than those of TGFβ1
(p<0.001, post hoc test) and TGFβ2 (p=0.013, post hoc test)
in ALCs. For PBMCs, the relationships were as follows: the
TGFβ3  mRNA  level  (Me=17650)  was  the  highest  and
significantly  greater  than  those  of  TGFβ1  (Me=1459,
p=0.002, post hoc test) and TGFβ2 (Me=190, p=0.012, post
hoc test). The mRNA level of TGFβ1 was also significantly
greater than that of TGFβ2 (p<0.001, post hoc test).
Correlations between transforming growth factor β1, β2, and
β3 messenger ribonucleic acid for anterior lens capsules and
peripheral blood mononuclear cells: All three isoforms were
positively correlated with each other in the ALCs of patients
with  congenital  cataracts.  However,  there  was  only  a
significant association between mRNA levels of TGFβ1 and
TGFβ2 for PBMCs (Table 3).
For traumatic cataracts, a positive correlation was only
observed between the expression of TGFβ1 and TGFβ2 in
ALCs, whereas for PBMCs, a positive correlation was only
affirmed between the expression of TGFβ1 and TGFβ3 (Table
3).
Differences in transforming growth factor β1, β2, and β3
messenger ribonucleic acid between congenital and traumatic
cataracts:  In  ALCs,  there  was  no  significantly  different
expressions  of  TGFβ1,  TGFβ2,  and  TGFβ3  between
congenital and traumatic cataracts (TGFβ1 p=0.78, TGFβ2
p=0.75, TGFβ3 p=0.23, Mann–Whitney U test). In PBMCs,
the  expression  of  TGFβ1  and  TGFβ2  was  about  twofold
higher in the congenital cataract patients compared to the
patients with traumatic cataracts, and a statistical significance
was  found  (TGFβ1  p<0.0001,  TGFβ2  p<0.0001,  Mann–
Whitney  U  test).  However,  no  statistically  significant
relationship was found for TGFβ3 isoforms (p=0.23, Mann–
Whitney U test; compare Figure 1A and Figure 1B).
Figure 1. The mRNA levels of transforming growth factor β isoforms in anterior lens capsules and peripheral blood mononuclear cells of
patients with clinically diagnosed congenital (A) and traumatic cataracts (B). Box and whisker plots present medians±quartiles and extreme
values of copy numbers per 1 μg of total RNA; p<0.0001, Kruskal–Wallis test.
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3028Relationships between transforming growth factor β1, β2, and
β3 messenger ribonucleic acid, gender, and left- or right-
sided cataracts: No statistically significant correlations were
found for congenital cataracts between the mRNA levels of
TGFβ isoforms and gender or left- or right-sided cataracts
(Table 4).
Correlations between transforming growth factor β1, β2, and
β3  messenger  ribonucleic  acid  and  patient’s  age  or  time
interval  between  trauma  and  surgery:  There  was  no
correlation between the age and transcriptional activity for
any of the TGFβ isoforms in the ALCs of the congenital
cataract samples collected during surgery (ALCs: TGFβ1,
r=0.180, not significant (NS); TGFβ2, r=0.168, NS; TGFβ3,
r=-0.011, NS). For PBMCs, a significant negative correlation
was only determined between the mRNA levels of TGFβ1 and
age (PBMCs: TGFβ1, r=-0.395, p<0.05; TGFβ2, r=-0.025,
NS; TGFβ3, r=-0.051, NS). Correspondingly to the results
obtained for congenital cataracts, in ALCs from the patients
with  traumatic  cataracts,  no  correlations  between  the
expression of TGFβ genes and age (ALCs: TGFβ1, r=-0.158,
NS;  TGFβ2,  r=0.110,  NS;  TGFβ3,  r=-0.046,  NS)  were
detected.  As  for  PBMCs,  a  positive  correlation  was  only
observed between TGFβ3 mRNA and age (PBMCs: TGFβ3,
r=0.657, p<0.05; TGFβ1, r=-0.395, NS; TGFβ2, r=-0.042,
NS).
Furthermore, correlations between TGFβ1, TGFβ2, and
TGFβ3 mRNA levels and time interval between trauma and
surgery were evaluated in our study. There was a significant
positive  correlation  only  between  the  mRNA  levels  of
TABLE 3. THE CORRELATIONS BETWEEN TGFβ ISOFORMS (COPIES/µG TOTAL RNA) IN THE ALCS AND PBMCS OF PATIENTS WITH CLINICALLY DIAGNOSED CONGENITAL AND
TRAUMATIC CATARACTS.
Congenital catarct
ALCs TGFβ1 mRNA TGFβ2 mRNA TGFβ3 mRNA PBMCs TGFβ1 mRNA TGFβ2 mRNA TGFβ3 mRNA
TGFβ1 mRNA - r=0.683* r=0.596* TGFβ1 mRNA - r=0.546* r=0.213
TGFβ2 mRNA r=0.683* - r=0.569* TGFβ2 mRNA r=0.546* - r=-0.129
TGFβ3 mRNA r=0.596* r=0.569* - TGFβ3 mRNA r=0.213 r=-0.129 -
Traumatic cataract
ALCs TGFβ1 mRNA TGFβ2 mRNA TGFβ3 mRNA PBMCs TGFβ1 mRNA TGFβ2 mRNA TGFβ3 mRNA
TGFβ1 mRNA - r=0.583* r=0.279 TGFβ1 mRNA - r=-0.218 r=0.673*
TGFβ2 mRNA r=0.583* - r=0.331 TGFβ2 mRNA r=-0.218 - r=-0.151
TGFβ3 mRNA r=0.279 r=0.331 - TGFβ3 mRNA r=0.673* r=-0.151 -
           Statistical significance: *p<0.05, Spearman rank correlation test.
TABLE 4. FACTORS ASSOCIATED WITH TGFβ ISOFORMS’ EXPRESSION CHANGES IN THE ALCS AND PBMCS OF PATIENTS WITH CLINICALLY DIAGNOSED CONGENITAL
CATARACTS.
Variable n TGFβ1* p** TGFβ2* p** TGFβ3* p**
Anterior lens capsules (ALCs)
Gender
M 21 9682 (4554–19139) NS 5119 (1967–15660) NS 1915 (1494–2845) NS
F 19 9162 (5792–24306)   8034 (2154–19968)   3082 (2062–8230)  
Eye
Right 18 11122 (5790–15423) NS 7161 (2518–18149) NS 2524 (1564–5017) NS
Left 22 8942 (4621–24306)   5119 (1967–18430)   2295 (1527–3888)  
Peripheral blood mononuclear cells (PBMCs)
Gender
M 21 3640 (1519–8691) NS 356 (295–529) NS 8998 (7261–15053) NS
F 19 4475 (2749–5010)   330 (265–506)   16768 (4119–35775)  
Eye
Right 18 4475 (1787–7761) NS 356 (300–552) NS 11827 (6327–35775) NS
Left 22 4070 (2121–7105)   308 (266–513)   9788 (6943–19801)  
         *Median  with  25th  and  75th  quartiles  (mRNA  copies/µg  total  RNA).  **U  Mann–Whitney  test.  NS  –  not  significant.
         Abbreviations M and F stand for male and female participants, respectively.
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3029TGFβ1  and  time  interval  between  trauma  and  surgery  in
PBMCs (r=0.595, p<0.05).
DISCUSSION
TGFβ  isoforms  and  their  receptors  are  expressed  in  both
normal and pathological lenses [2,18,29]. Determination of
differences  between  mRNA  levels  in  cataractous  lens
capsules compared and normal ones seems to be important.
Previous research has revealed elevated levels of TGFβ in
cataractous lenses in comparison to those in noncataractous
ones [30]. Therefore, this report focused only on quantitative
relations between TGFβ isoforms in congenital and traumatic
cataracts. In the present study, real-time QRT–PCR was used
to  evaluate  copy  numbers  of  TGFβ1,TGFβ2,  and  TGFβ3
mRNA. All three TGFβ isoforms were detected in ALC and
PBMC samples, which is partially consistent with the results
obtained  by  Gordon-Thomson  et  al.  [2].  These  authors
demonstrated the presence of TGFβ1 and TGFβ2 mRNA in
various ocular tissues, including the lens. TGFβ3 mRNA was
only  detected  in  the  retina  and  choroid.  However,  they
observed mRNA distribution in ocular tissues using in situ
hybridization methods.
Our  results  revealed  that  TGFβ1  was  a  predominant
isoform in ALCs, whereas TGFβ3 was a major isoform in
PBMCs in patients with congenital and traumatic cataracts.
Our observation is supported by the data published by Lee et
al. [30], who indicated the strongest expression of TGFβ1
mRNA  in  human  lens  epithelial  cells  from  patients  with
anterior polar cataracts. Similar results were demonstrated by
Carrington et al. [31], who found TGFβ1 to be a predominant
isoform in the bovine cornea during wound healing. However,
the  real-time  QRT–PCR  technique  was  not  used  in  these
studies.
Shirai et al. [32] also performed studies where epithelial
mesenchymal transition lens cells expressed TGFβ1,TGFβ2,
and TGFβ3 isoforms. This remains consistent with current
results showing the presence of all three TGFβ isoforms in
both types of cataracts. In ALCs, similar mRNA levels of
predominant  TGFβ1  and  TGFβ2  isoforms  were  found.
Whereas Shirai et al. [32] only determined the increase of both
active and total TGFβ2 in the injured rat lens and aqueous
humor, according to Yoneda et al. [33], the concentration of
TGFβ3 was much lower than the content of other two isoforms
in the aqueous humor, which confirms our observations for
ALC tissues.
Xiao  et  al.  [34]  revealed  an  overaccumulation  of
TGFβ1 and basic fibroblast growth factor mRNA in the lens
with anterior subcapsular congenital cataracts when compared
to  transparent  lenses.  In  our  study,  it  was  observed  that
TGFβ1 mRNA levels in ALC patients were raised, but there
were  no  significant  differences  in  its  levels  between
congenital  and  traumatic  cataracts,  which  partially
corresponds to the research results of Xiao et al. [34]. The
dissimilarity might have resulted from the selection of our
control  group,  i.e.,  including  pediatric  patients  who  had
sustained an eye injury rather than patients with clear lenses.
The lack of significant differences between the two types of
cataractous lenses suggests that TGFβ may mediate at least
some part of cataractogenesis for both types.
Previous studies indicated that traumatic events could
result in the activation of the TGFβ signaling pathway [17,
18]. Wallentin et al. [35] demonstrated the activation of the
TGFβ superfamily signaling pathway following experimental
cataract surgery in rabbits. Furthermore, these authors showed
that the level of total TGFβ in postoperative aqueous humor
was continually increasing. Likewise, our results revealed
higher  mRNA  levels  of  TGFβ1  and  TGFβ2  in  ALCs  of
traumatic cataract patients. However, these results were not
statistically significant when compared to those obtained for
congenital cataracts. The results shown above may indicate
that cataract surgery increases the level of TGFβs.
TGFβ has been found in human plasma, platelets, and
circulating leukocytes [36-38]. It is known that the expression
of TGFβ is constitutive in leukocytes and does not depend on
activation [36]. Therefore, it seems a proper biologic material
for the determination of TGFβ levels in blood. Our results for
the quantitative relationships between three TGFβ isoforms in
PBMCs are in accordance with other studies’ results [38].
Interestingly, the subjects with congenital cataracts showed a
significant  elevation  of  TGFβ1  and  TGFβ2  expression  in
PBMCs when compared to those with traumatic cataracts,
which suggests that traumatic cataractogenesis is mediated
differently  from  congenital  cataractogenesis.  The  most
striking difference concerned TGFβ1. Chan et al. [39] studied
the plasma level of the TGFβ1 transgene in hybrid mice.
Although the expression of the TGFβ1 transgene was only
targeted to the liver, its overexpression resulted in hepatic and
multiple  extrahepatic  lesions.  In  the  eye,  there  was  a
progressive cortical cataract formation. In our research, the
upregulation of TGFβ1 and TGFβ2 gene expression in the
PBMCs of patients with congenital cataracts might suggest
that  the  processes  occurring  in  the  lens  are  affected  by
systemic  expression  levels  of  these  cytokines,  especially
during fetal life when the lens is vascularized.
The second part of this study focused on the correlations
between TGF isoforms in congenital and traumatic cataracts.
Interestingly, in the ALCs of congenital cataract patients, all
three  TGFβ  isoforms  were  positively  correlated,  but  in
traumatic  cataract  patients,  there  were  only  positive
correlations  between  the  mRNA  levels  of  TGFβ1  and
TGFβ2.  Moreover,  in  the  PBMCs  of  congenital  cataract
patients,  only  TGFβ1  and  TGFβ2  exhibited  positive
association, whereas in the traumatic cataract patients, the
TGFβ1 and TGFβ3 isoforms were correlated. The relations
between the levels of TGFβ1, TGFβ2, and TGFβ3 and their
biologic effects may be explained through TGFβ binding to
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share  the  same  receptors  for  their  signal  transduction,  a
specific pathological role played by TGFβs might result from
their different activity or potency [33].
In the studies performed by Rostkowska-Nadolska et al.
[40],  TGFβ1  transcriptional  activity  was  accompanied  by
TGFβ2 transcriptional activity in nasal polyps, which is in
accordance with the observations of their activity in the lenses
of our study. The TGFβ2 isoform is structurally similar to
TGFβ1, but the biologic responses to these cytokines differ
depending on the cell type. The promoter sequences of the
genes coding different TGFβ isoforms are not homologous.
The analysis of TGFβ1 and TGFβ3 promoters revealed the
presence of several binding sites for the transcriptional factors
Sp-1  and  AP-1.  Fragments  of  the  TGFβ1  and  TGFβ3
promoters may compete for binding of Sp-1 to DNA. The
TGFβ2 promoter does not contain binding sites for the Sp-1
transcriptional factor [41]. The lack of correlation between
TGFβs may result from similar regulation of the expressions
of these genes and competition for binding Sp-1.
Our  data  regarding  congenital  cataract  revealed  age-
dependent  differences  in  the  mRNA  levels  of  TGFβ1  in
PBMCs.  These  observations  correspond  to  those  of  other
researchers, who demonstrated that serum TGFβ1 levels tend
to decrease with age [24,25]. However, Rungger-Brändle et
al. [42] did not show any correlation between the TGFβ2
mRNA levels and the age of the donors of the lenses without
visible opacity, lenses with mature cataracts, and cataractous
lenses  with  posterior  subcapsular  opacity  or  anterior
subcapsular fibrosis, which is consistent with our results. On
the other hand, it was found that rodent lens cells showed
enhanced  TGFβ  receptors  expression  and  increased
susceptibility to the cataractogenic effects of TGFβ with age.
This may suggest that the age-dependent increase in TGFβ
signaling is connected with the responsiveness of the target
tissue rather than with TGFβ expression itself [43,44].
Correlations  between  TGFβ2  levels  and  history  of
cataract  surgery  (time  interval  between  previous  cataract
surgery and the evaluation of TGFβ2 concentrations) were
observed  in  aqueous  humor  [45].  Taking  into  account
Wallentin’s results [35], which show a continuous increase in
total TGFβ after cataract surgery throughout the study period
(30 days), the correlations between TGFβ gene expression and
the time interval between trauma and surgery were evaluated
in  our  studies.  Our  results  revealed  similar  positive
correlations between TGFβ1 mRNA level and time interval
between trauma and surgery for PBMCs. These observations
might  suggest  that  the  accumulation  of  TGFβ  promotes
cataractogenesis.
At present, it is difficult to determine whether systemic
TGFβ1 and TGFβ2 overexpression in congenital cataracts
might act as a causative or concomitant factor. For instance,
Marfan syndrome is believed to result from mutations in the
gene encoding fibrillin-1. However, recent research has shed
new light on the role of TGFβ in the pathogenesis of this
disease. Interference of TGFβ signaling has been found to be
involved in aortic aneurysm formation and progression. What
is more, the disruption of TGFβ pathways might provide new
diagnostic and therapeutic options [46,47]. Perturbations of
TGFβ  signaling  might  also  underlie  some  proportion  of
congenital  cataracts.  Further  studies  are  needed  to
conclusively confirm the cataractogenic influence of TGFβ.
In conclusion, all three TGFβ isoforms were found to be
differentially expressed in the ALCs and PBMCs of pediatric
patients  with  congenital  and  traumatic  cataracts.
Overexpression  of  TGFβ1  and  TGFβ2  in  the  PBMCs  of
patients  with  congenital  cataracts  might  indicate  the
involvement of these cytokines in the development of lens
opacity.
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